Ketamine Research and Policy Updates
News and research summaries focused on what changes in evidence, regulation, access, and clinical practice may mean for ketamine patients and providers.
What belongs here
Current research, policy, FDA, DEA, trial, and access updates with patient-facing context and links to primary sources when available.
What to read next
Use news articles for context, then move to the evergreen guide or safety hub for durable treatment planning information.
Need help or want to reach readers?
Have a correction, provider question, or advertising inquiry? Reach the editorial team.
Featured
3 articles
2026 Psychedelic Policy Shifts: What Patients Should Know
A wave of state and federal psychedelic legislation in April 2026 could reshape the therapeutic landscape — here's what ketamine patients need to know.
Ketamine Therapy for Couples: What the Research Shows
Can couples do ketamine therapy together? What 2026 clinical research shows about ketamine for marriage, relationship repair, and joint dosing sessions.
FDA Clears Trial Pairing Ketamine Follow-Up Drug With TMS
The FDA cleared the MIND1 trial testing NRX-101 with robotic TMS for treatment-resistant depression and suicidality. What ketamine patients should know.
2026 Psychedelic Policy Shifts: What Patients Should Know
A wave of state and federal psychedelic legislation in April 2026 could reshape the therapeutic landscape — here's what ketamine patients need to know.
Ketamine Therapy for Couples: What the Research Shows
Can couples do ketamine therapy together? What 2026 clinical research shows about ketamine for marriage, relationship repair, and joint dosing sessions.
FDA Clears Trial Pairing Ketamine Follow-Up Drug With TMS
The FDA cleared the MIND1 trial testing NRX-101 with robotic TMS for treatment-resistant depression and suicidality. What ketamine patients should know.
CBT After Esketamine Boosts Depression Outcomes in Trial
A new randomized trial finds that adding 16 weeks of CBT after esketamine significantly improves depression and suicidal ideation compared to esketamine alone.
FDA Clears NMDA Drug for Alzheimer's Agitation — What It Means for Ketamine Patients
The FDA approved Axsome's AXS-05 for Alzheimer's-related agitation. Here's what this NMDA antagonist approval means for ketamine therapy patients and the field.
FDA Fast-Tracks Psychedelics for Depression, PTSD, and AUD
The FDA is accelerating psychedelic drug development for treatment-resistant depression, PTSD, and AUD. What it means for patients exploring ketamine therapy.
AXS-05 Nears FDA Decision for Alzheimer's Agitation
AXS-05, an oral NMDA-targeting drug, nears FDA approval for Alzheimer's agitation. Here's what it means for the ketamine treatment landscape.
Side Effects & Dropout Rates: New Data on Ketamine for TRD
New clinical guidance on NMDA antagonist side effects and dropout rates offers practical insight for patients considering ketamine therapy for TRD.
Why Patients Quit NMDA Therapy—And What Providers Should Do
New clinical review urges faster dose optimization and earlier switching between NMDA therapies for treatment-resistant depression. Here's what it means for patients.
When to Push for Stronger TRD Treatments, Per Experts
Psychiatric Times highlights underuse of highly effective TRD treatments. Here's what this means if you or a loved one is stuck in a cycle of failed antidepressants.
Trump Signs EO to Speed Psychedelic Research & Access
President Trump signed an executive order accelerating psychedelic research and access in April 2026. Here's what it means for ketamine therapy patients.
NMDA Side Effects: What Dropout Rates Mean for Patients
New clinical guidance on NMDA antagonist side effects and dropout rates offers practical insights for patients considering ketamine or esketamine therapy.
Ketamine Side Effects: What New Clinical Data Reveals
New clinical analysis examines side effect profiles and discontinuation rates for ketamine and esketamine. Here's what treatment-resistant depression patients should know.
NRx's Preservative-Free Ketamine Moves Through FDA Review
NRx Pharmaceuticals reports progress on its FDA application for a preservative-free ketamine formulation. What patients should know about this development.
Psychedelics Executive Order: What It Means for Ketamine Patients
A new executive order targeting psychedelic medicines is reshaping the regulatory landscape. Here's what ketamine therapy patients should understand.
BPL-003 Shows Lasting Relief in Treatment-Resistant Depression
New phase 2a data on BPL-003 shows sustained symptom reduction in treatment-resistant depression. What patients should know about this emerging therapy.
Ketamine Side Effects: What New Data Tells Patients
A new clinical review examines side effect profiles and discontinuation rates for NMDA antagonists like ketamine and esketamine. Here's what patients should know.
Ketamine Side Effects: What New Data Means for Patients
New clinical guidance on NMDA antagonist side effects and discontinuation rates gives patients and families sharper questions to ask before starting ketamine therapy.
How Doctors Choose Ketamine vs. Other TRD Treatments
New clinical guidance explains how psychiatrists choose between esketamine, ketamine, and brain stimulation for treatment-resistant depression patients.
Cambridge Joins UK's Growing Psychedelic Research Push
Cambridge University has added its weight to UK psychedelic research. Here's what this institutional shift means for patients considering ketamine therapy.
Esketamine's Role in Treatment-Resistant Depression Care
Where esketamine (Spravato) sits in 2026 treatment-resistant depression care: FDA-approved indications, response rates after SSRI failure, access barriers, and how it compares to generic IV and at-home options.
New Ketamine Nasal Spray Shows Lasting Depression Relief
Phase 2a trial results for BPL-003, a ketamine-based nasal spray for treatment-resistant depression, show sustained symptom reduction. Here's what it means.
BXCL501 Phase 2a Trial Targets Acute Stress & PTSD Prevention
A new DoD-backed Phase 2a trial tests BXCL501 for acute stress reactions and PTSD prevention. Here's what this means for patients exploring trauma treatment.
New PTSD Prevention Drug Trial Enrolls First Patients
A DoD-backed Phase 2a trial is testing BXCL501 for acute stress reactions and PTSD prevention. Here's what ketamine patients should understand.